InfuSystem Holdings, Inc.
New York Stock Exchange AmericanCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Carrie A. Lachance
- Full Time Employees
- 502
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- Address
- 3851 West Hamlin Road Rochester Hills MI United States of America 48309
- IPO Date
- Dec 27, 2007
- CIK
- 0001337013
- Website
- infusystem.com
- Similar Companies
- Business
- InfuSystem Holdings, Inc. is a leading national healthcare service provider that facilitates outpatient care for durable medical equipment manufacturers and healthcare providers through infusion pumps, related services, and biomedical solutions. Headquartered in Rochester Hills, Michigan, with Centers of Excellence in Michigan, Kansas, California, Massachusetts, Texas, and Ontario, Canada, the company operates primarily in the United States and Canada, serving hospitals, oncology practices, ambulatory surgery centers, and other alternate-site providers; it was spun off in 2005 from I-Flow Corporation and trades on the NYSE American under the symbol INFU. The company conducts business across two main platforms: Patient Services, encompassing oncology, pain management, and wound therapy with integrated clinic-to-home solutions including equipment logistics, 24/7 nursing support, third-party payer billing, and treatment consumables; and Device Solutions, offering sales and rentals of new and pre-owned ambulatory, pole-mounted, and large-volume infusion pumps, other durable medical equipment, pump and consumable sales, as well as on-site and depot biomedical repair, maintenance, inspection, certification, and replacement services for infusion pumps, patient monitors, and ESUs. Recent developments include an exclusive U.S. distribution agreement with ChemoMouthpiece, LLC for the prescription-only Chemo Mouthpiece oral cryotherapy device to reduce oral mucositis in chemotherapy patients, supported by a minority investment; a distribution agreement with Smith+Nephew for the RENASYS EDGE negative pressure wound therapy system and supplies in home-based care; the merger of Biomedical, Inc. into InfuSystem on January 1, 2024; a small acquisition in Q2 2025 to enhance advanced wound care processing technology; strategic investments in direct rentals; and ongoing stock repurchases totaling $6.4 million in the first half of 2025, alongside robust financial performance with record Q3 2025 net revenues of $36.5 million and Q2 2025 Adjusted EBITDA margin expansion to 22.3%.
Should Value Investors Buy InfuSystems Holdings (INFU) Stock?
Does InfuSystems Holdings (INFU) Have the Potential to Rally 62.61% as Wall Street Analysts Expect?
Here is Why Growth Investors Should Buy InfuSystems Holdings (INFU) Now
Are Investors Undervaluing InfuSystems Holdings (INFU) Right Now?
What Makes InfuSystems Holdings (INFU) a New Buy Stock
Looking for a Growth Stock? 3 Reasons Why InfuSystems Holdings (INFU) is a Solid Choice
InfuSystem Announces $20 Million Stock Repurchase Program
InfuSystem Holdings, Inc. (INFU) Shareholder/Analyst Call Prepared Remarks Transcript
Is InfuSystems Holdings (INFU) Stock Undervalued Right Now?
InfuSystem Holdings, Inc. (INFU) Q1 2026 Earnings Call Transcript
InfuSystems Holdings, Inc. (INFU) Q1 Earnings Top Estimates
InfuSystem Announces Financial Results for First Quarter 2026
InfuSystem to Report First Quarter 2026 Financial Results on May 7, 2026
InfuSystem (NYSE:INFU) Stock Price Down 1.3% – Time to Sell?
InfuSystem: Expecting Strong Stock Gains In 2026
InfuSystem to Participate at 38th Annual ROTH Conference on March 23, 2026
Reviewing InfuSystem (NYSE:INFU) and Nemaura Medical (OTCMKTS:NMRD)
InfuSystem Holdings, Inc. (INFU) Q4 2025 Earnings Call Transcript
InfuSystems Holdings, Inc. (INFU) Q4 Earnings Beat Estimates
InfuSystem Announces Financial Results for Fourth Quarter and Full Year 2025